Preprint
Concept Paper

This version is not peer-reviewed.

Conflammation: Too Much Conflation in Inflammation?

Submitted:

06 November 2026

Posted:

09 November 2026

You are already at the latest version

Abstract
The use of the word inflammation in recent literature appears to have superseded the classical definition of the word. However, a precise new definition has not yet emerged. As a result, the boundaries of the concept are hazy and it needs to be examined critically whether everything in the semantic basket is indeed “inflammation”. Similar to almost all genes, molecules and pathways, inflammation associated cells and molecules also have a number of other normal physiological functions. Altered expression of these can be associated with functions other than defence. If all these functions are also to be called inflammation, in the entire life ranging from embryo implantation to death, the body can be said to be always in a state of inflammation. This takes aways the need for the concept itself. As a result of the ambiguous definition, inflammation has been blamed for a number of health disorders but anti-inflammatory treatment has failed to cure or prevent them. In particular the concept of chronic systemic inflammation is laid with multiple anomalies which might be misleading our understanding of health and medicine. On the foundation of evolutionary logic, a new and clearer perspective of the condition called chronic systemic inflammation can emerge. We discuss the foundations of the new perspective and its relevance to health, disease and medicine.
Keywords: 
;  ;  ;  ;  
Inflammation has become a key term in biomedicine used extensively in various contexts, but rather loosely and ambiguously. The concept has undergone a number of major transitions in core definition, working definition, tools for detection and perceived relevance in medicine. A problem arising because of the rapid transitions is that the classical definitions are no more valid but a precise new definition has yet not emerged clearly and unambiguously. The problem goes beyond semantics and affects the conceptual foundations of physiology, immunology and medicine. With huge amounts of genetic, molecular, cellular, metabolic, immunological intricacies coming to light every now and then, the field appears to have lost in details. With the intriguing amount of information, more internal contradictions and conceptual anomalies are accumulating which need to be addressed seriously. We do not claim to resolve the anomalies at one go, but attempt to point out the critical issues that need to be addressed starting with definition and suggest a possible novel platform based on which a coherent sense can emerge.

I. Historical Context of Definition of Inflammation

The definition of inflammation has gone through three major phases of transition. The ancient clinical context of inflammation “Notae vero inflammationis sunt quatuor: rubor et tumor cum calore and dolore” stems back to the 1st century AD defining the four cardinal signs of inflammation, namely redness, swelling, fever and pain by Arnus Cornelius Celsus. The fifth sign, functio laesa or “loss of function,” was introduced later. Influentially, Galen (3rd cent. A.D.) redefined inflammation (Phlogosis) as a reaction of the body against injury. These early ideas were shaped only by the available tools and knowledge of biology and therefore were symptoms based 1–3.
Approaching the 19th century, advances in microscopy and cell biology opened the door to second phase, i.e. the cell-based definitions of inflammation. It was for Elie Metchnikoff (1845–1916), that the view on inflammation was shifted to immune cell accumulation and phagocytosis. Neumann (1889) included the healing or restorative component to the definition. Immune cell aggregation was identified as the core of the inflammation process.
The molecular mechanisms of all these functions of the cells were being discovered from the middle of the 20th century. Sir Henry Dale in 1930s, primarily reframed inflammation as a process mediated by endogenous active substances (acetylcholine, histamine, catecholamine) formed, synthesized or released by the body. The field advanced further with more and more molecules being discovered one by one such as histamine, leukotaxin (chemokines), bradykinin, interleukins, pyrogenic cytokines, C-reactive protein (CRP), and interleukins 3,4. As a consequence, the end of 20th century shifted the focus from cells to molecules. Today the working definition depends upon showing raised levels of one or a few “inflammatory markers”. It is no more considered necessary to demonstrate cell aggregation, the site of aggregation, phagocytosis or other cell interactions and their actual relevance to defence and healing. Implicit behind this working definition is the assumption that the molecules used as inflammatory markers are specific to inflammation alone and always faithfully represent inflammation as defined at the cellular level. Throughout this phase of the transition, the cellular definition of inflammation has not been formally dismantled 3,4. The use of the word inflammation today often appears to relate to anything that “immune cells” do or any altered expression of the molecules labelled “inflammatory markers”. But the ‘anything’ component of the perception needs a critical look.

II. Burden of History, Burden of Simplicity & the Perception Bias

We know today that almost no gene, protein or pathway has a single function. Typically, in physiology a gene or molecule is first discovered in a certain context and gets a name and builds an “image” in that specific context. Later many other functions of the same entity are discovered but still in popular image we continue to perceive the entity in its first discovered context. This is a burden of history that might create a bias in our perception. For example, insulin was discovered in the context of diabetes and glucose regulation. We know today that apart from glucose regulation, insulin has a wide range of functions spanning stem cell maintenance, tissue homeostasis, protein metabolism, angiogenesis, sex, reproduction, memory and behavioral decisions 5–8. But if there is a change in plasma insulin levels, we almost invariably relate it to glucose, insulin resistance and diabetes in some way or the other. Even in the context of glucose regulation, it is clear now that the role of insulin is not as it was perceived classically 9,10. But rather than acknowledging the more complex and evidence -based picture, diabetes medicine continues to go by the oversimplistic classically perceived role. We continue to perceive the systems as modular although they are shown to work as networks 10. Thus, both the burden on history and burden of simplicity shape our perception of a cell, gene, molecule or a pathway. Many more examples illustrate the phenomenon.
Classically understood as a “bone formation marker”, osteocalcin is now known to be involved in multiple functions in the body like that of metabolism, reproduction and brain function. It enhances adiponectin release from adipose tissue, improves glucose tolerance and energy metabolism in muscle. It also supports exercise adaptation by promoting glucose and fatty acid utilization, influences male fertility by boosting testosterone production in Leydig cells, and regulates brain development and cognition through effects on neurotransmitter synthesis and hippocampal growth 10–13. Still the primary perception of osteocalcin is in the context of bone health.
Similarly, the “adipose tissue” is a multi-functional endocrine organ, that secretes leptin, adiponectin, and resistin, stores energy, regulates glucose homeostasis, controls lipid metabolism and steroid hormone conversion. The tissue also plays a role in adipokines that influence appetite, insulin sensitivity, blood pressure, and inter-organ communication. In essence, adipose tissue is far more than a fat-storage organ, it is a complex, hormonally active tissue that integrates metabolic, immune, vascular, structural, and behavioural signals across the entire organism. But in our perception, the “primary” function of adipose tissue still remains storage of excess energy 14,15.
First known by the observation that it inhibits macrophage migration and hence named the Macrophage Migration Inhibitory Factor (MIF), the molecule is now known to have diverse pro-inflammatory and anti-inflammatory functions. Several studies have demonstrated that MIF has proinflammatory roles for example, it maintains macrophage priming through TLR4 upregulation and acts as a critical autocrine/paracrine regulator of macrophage activation through TLR4 16, it sustains MAPK signalling while overriding glucocorticoid suppression 17, activates the NLRP3 inflammasome 18, it drives chemokine release through CD74 receptor engagement 19, induces TNF production in monocytes and macrophages 20, and enhances NFκB-dependent antimicrobial responses 21. It was also found that MIF deficiency results in reduced expression of inflammatory mediators like IL-1β, CCL2, and MMPs, and increased production of anti-inflammatory cytokines such as IL-10 in the lesion area, suggesting that MIF can induce anti-inflammatory effects as well. 22. Furthermore, studies have shown MIF to have neuroprotective effects by inducing expression of BDNF. Similarly, MIF is found to upregulate serotonin, THP2 and BDNF in vitro as well as during exercise 23. MIF was found to be released in the ischemic heart, it stimulates AMPK, a master energy-sensing enzyme that increases cellular ATP production and limits energy consumption 24. Given the span of functions of MIF, the name is a complete misnomer, but still continues to be used and inevitably shapes the perspectives of a person entering the field.
Heat Shock Proteins, first known for the intracellular chaperone functions of protein homeostasis, protein folding and refolding, aiding in the removal of defective proteins, cell signalling transduction, cell cycle, and apoptosis regulation, HSPs also serve as danger signal molecules to alert the immune cells to recognize the existence of damaged cells 25,26.
The diverse examples demonstrate how the cells and molecules are often named in the context of discovery and that often continues to be perceived as their “primary” function. This burden of history and burden of simplicity has haunted the field of immunology too. We see that the cells perceived as “immune cells” have many other functions not directly related to injury and infection. Similarly, molecules primarily discovered in the context of immune function are shown to have other normal physiological functions too. But we are biased in our perception and we continue to see them as “immune cells” and “inflammatory markers”. If we see any change in the population and behavior of cells or expression and standing levels of the molecules, we immediately call it inflammation without considering the possibility that it might be in some other context too. Therefore, we need to look carefully at alternative functions of these cells and molecules and decide whether they always reflect inflammation as perceived today. The functions of immune cells not directly related to innate immunity are worth highlighting as they are an important part of a system that works like networks, not as modular mechanisms 27,28.

III. The Non-Defensive Functions of Immune Cells

Although macrophages are perceived primarily in the context of immunology, their functions are diverse and start right from embryonic life where infection and injury stimuli are almost non-existent or taken care by the maternal immune system. Macrophages are critical in embryo implantation. Abnormal macrophage distribution, number, or polarization is linked to recurrent implantation failure (RIF) 29 . The placental macrophages of foetal origin, called “Hofbauer cells” play a key role in angiogenesis, vasculogenesis and placental mesenchyme development 30. Interestingly the signals involved in the developmental and re-modelling functions are IL-8 and MMP-9 which are also recognized as pro-inflammatory signals.
In adult life, macrophages play an essential role in maintaining tissue balance by clearing dead cells, apoptotic cells, and cellular debris, which helps preserve tissue integrity. This includes efferocytosis, the removal of effete/senescent cells before they trigger more damage. Although this role has parallels with the phagocytosis role in inflammation, it is a part of normal physiology, not triggered by any infection or injury challenge. Furthermore, macrophages play an active role in lipid metabolism and adipose tissue regulation; regulation of ECM and collagen synthesis; angiogenesis; iron homeostasis in the liver; and growth factor expression 31,32.
The name Natural Killer cells is a glaring example of burden of history. The non- destructive functions of NK cells can be traced to reproduction, pregnancy and foetal development. NK cells play a crucial role in facilitating endometrial tissue remodelling, supporting vascular function, and contributing to placental formation. The uterine NK cells, like endometrial NK (eNK) cells and decidual NK (dNK) cells, act as regulators of placentation. They are primarily involved at the maternal-foetal interface in driving angiogenesis on the maternal side and vasculogenesis on the foetal side. The dNK cells regulate uterine spiral artery development, and control the oxygen supply at the maternal foetal interface as well as ensure a good maternal-foetal blood supply 33 . The uterine NK cells secrete osteoglycin that regulates collagen fibril structure and contributes to fetal heart and tissue development 34. Improper functioning of dNK cells at the maternal-foetal interface leads to placental dysfunction 35–37.
B cells are found to be abundant especially during embryonic brain development. They are directly linked to developing-brain processes and are known to support oligodendrogenesis and myelination. Additionally, B cells are involved in remyelination by producing natural antibodies (nAbs) against unidentified myelin antigens 38–43. T cells are involved in complex brain processes including spatial learning, memory, emotional behaviour and stress responsiveness 44.
Given the span of functions of these cells, calling them “immune cells” appears to be a burden of history. If their role in embryonic development was to be discovered first, we might have called them developmental cells and said that they also contribute to immune function as a secondary role.

IV. Non-Defensive Functions of the So Called Inflammatory Markers:

Similarly, what we call inflammatory markers today also have a set of different functions. It is hence unfair to assume that an altered or elevated level of inflammatory markers is directly linked to inflammation. Exercise for example, triggers high levels of IL-6, but this is not accompanied by elevated IL-1β or TNF-α (the canonical pro-inflammatory cytokines). Instead, exercise-induced IL-6 stimulates anti-inflammatory molecules like IL-10 and IL-1ra. Here, IL-6 leads muscle to utilize fatty acids and promotes a shift from catabolic, glucagon-dependent pathways to anabolic, insulin-dependent pathways, helping glucose absorption by muscle and contributing to recovery. Thus, IL-6 plays an important role in metabolic regulation in the muscle tissue. It stimulates lipolysis and releases energy sources into bloodstream. It also stimulates insulin secretion and insulin sensitivity. It induces proteolysis in muscle, making amino acids available for protein synthesis. Similar to leptin, IL-6 functions as an indicator of energetic status. Higher levels signal that more energy is available and can be allocated to maintenance functions such as tissue repair. In adipose tissue, IL-6 production may indicate that when stored energy is available it is allocated to somatic maintenance, which is called as “adaptive metabolic allocation”, that has nothing to do with inflammation 45. Furthermore, IL-6 contributes to appetite suppression and delayed gastric emptying, thereby attenuating postprandial glycemia. Beyond metabolic regulation, IL-6 plays critical roles in skeletal muscle hypertrophy and bone re-modelling 46.
CRP, another commonly used inflammatory marker also has other normal functions. CRP exists in two isoforms. In its monomeric form (mCRP) it acts as a chemoattractant and is generated at the site of injury, which is at the core of classical inflammation. CRP in its pentameric form (pCRP) is involved in wound healing, clearance of damaged cells, and tissue regeneration which can be considered a legitimate part of inflammation. However, tissue repair and maintenance is also a normal process that continues in the absence of any injury or infection trigger and it is suggested that pCRP is produced for this purpose even without inflammation. In 2018, Giudice et al. 45 argue that moderately elevated levels of IL-6 and CRP can occur in the complete absence of inflammation and tend to have anti-inflammatory effects.

V. Need to Ask a Fundamental Question:

Does elevated level of an inflammation associated molecule necessarily reflect elevated inflammation?
To understand how inflammation works, it is important to understand the principle behind how immune cells aggregate at site of injury. Here, gradient is the key. The chemo-attractants act as signaling molecules that form concentration differences in the body. The concentration differences lead to formation of gradients. The strength of such a gradient depends upon the level of the chemoattractant molecules at the site of injury (local level) and the basal systemic level. The gradient allows the immune cells to migrate to the appropriate location. When the basal levels rise, the gradient weakens. Therefore, it is likely that higher levels of some of the inflammatory markers tend to decrease rather than increase the inflammatory response. It might be misleading therefore to assume that a higher level of a molecule involved in cell migration response always indicates higher inflammatory response 47.
Innate immunity is a spatiotemporal process. Cells migrate based on different signals. The relative concentrations of molecules at different locations may be more important than the absolute ones. The same molecule may have different effects based upon where it is secreted, what are its relative levels at different locations, which other signals accompany it and which cell and receptors it interacts with. The downstream pathways of cell surface receptors and soluble receptor molecules can be very different 48–51.
Therefore, inferring anything from the raised levels of one or a few molecules can be misleading. For the same reason, classifying molecules into pro- versus anti-inflammatory is too simple to be true and useful. Many molecules have been claimed as both pro and anti-inflammatory in different contexts. Further the repeated failure of anti-inflammatory treatments to prevent the disorders believed to result from chronic systemic inflammation, in spite of reducing the marker levels 52–57 necessitate fundamental rethinking of inflammation and its associated pathophysiology.

VI. Potential Absurdities/Anomalies That Need Critical Re-Examination

Systemic inflammation: Systemic inflammation is characterized by the heightened levels of inflammatory mediators, like cytokines, chemokines, and acute phase proteins like CRP. It is said to be a whole-body inflammation response. The cellular process of inflammation comprises aggregation of immune cells. Aggregation is a locale specific process and it is absurd to say that they aggregate everywhere. Clearly the concept of systemic inflammation is not compatible with the classical cell aggregation-based definition. If the working definition of systemic inflammation is based on one or a few markers, it can be misleading as argued earlier. If it is about activation of immune mechanisms, one would expect that with systemic inflammation, the system would be ready to launch a quicker response to injury/infection leading to rapid recovery. But in contrast, in the disorders like diabetes characterized by systemic inflammation, wound healing is typically delayed or impaired 58,59 and the frequency and severity of cutaneous infections is higher 60,61.
Inflammaging: With age the level of systemic inflammation is said to go up and that is assumed to be central to the age-related changes in body functions and health, a phenomenon called inflammaging. A serious problem with this argument is that the association between aging and inflammatory markers is not consistent across human communities. The data behind inflammaging comes mainly from the western, educated, industrialized, rich, and democratic (WEIRD) societies. However, only 11% of the world’s population lives in these societies. Hence, WEIRD societies are not necessarily a good model for studying inflammation. Different societies, like the Filipino and Shuar communities showed low levels of aging associated CRP than the WEIRD societies. McDade 62 suggests that different communities show a distinctly different pattern, hence one should not assume that inflammation increases with age, and concepts such as “inflammaging” must be used carefully.
Is this inflammation? Without any explicit definition, the word inflammation is being used for anything that the so called “immune cells” do. For example, the role that macrophages play in embryo implantation has also been called inflammation 29,32,63. The ambiguity as to whether the response of these cells to defence related triggers is to be called inflammation or anything that these cells do will be called inflammation needs to be resolved first. In the case of the latter, even embryonic development, metabolism and normal tissue homeostasis will have to be called inflammation. This means that right from zygote formation to death, the body is in a continuous state of inflammation. This makes terms like the “inflammatory response” meaningless. If the behaviour of these cells above normal is to be called inflammation, the distinction between normal and danger triggered responses needs to be clarified first.
The cause-effect confusion: Macrophages play a role in lipid metabolism and the formation and maintenance of adipose tissue 31. Thus, there is an association between adipose tissue and macrophages. Does this mean that adipose tissue “causes” inflammation? It is necessary to look at this and many other associations critically for cause-effect relationships so as to avoid misinterpretations.
The Good-bad connotation: Almost throughout the literature on chronic inflammation, the word is used with negative connotation. Is inflammation always bad? If so, how did it survive the selective forces during evolution? The evolutionary underpinnings of physiology and pathophysiology are yet very superficially understood. Everything that we theorize in this field needs to withstand robust evolutionary analysis. Evolutionary medicine is no more a speculative field, it is rapidly becoming robust, testable and applicable foundation of all our understanding of physiology and medicine 64. If any mechanism of the body is harmful to itself, the question why it remained evolutionarily stable needs to be addressed critically and systematically. Any evolutionary hypothesis needs to be backed by sound evolutionary principles, make differential testable predictions and contribute novel insights to our understanding of health and disease 64. Handwaving arguments are no more acceptable in evolutionary medicine. The immune system being highly complex, insights into its evolution have started emerging only recently 65.

VII. An Evolutionary Interpretation of “Chronic Systemic Inflammation”:

One of the principles of evolutionary medicine is the mismatch hypothesis 6. The mechanisms of our body evolved for a set of ecological challenges faced by the ancestors and are optimized for it. But today’s lifestyle is substantially different than what we evolved for. It is possible that a system that was adaptive in one context can turn maladaptive in a mismatched context. Mainstream evolutionary medicine has discussed a limited range of mismatches such as the dietary mismatch and the fight or flight response. There are more mismatches whose potential effects have not been appreciated so far. Understanding evolutionary mismatch has two distinct components, the first one being why and under what context the system evolved and second, what kind of mismatch makes it maladaptive and how.
During human evolution, a unique change was the loss of fur, which changed the nature of innate immune challenges for the skin. In mammals, two distinct systems are involved in recruiting immune cells to the cutaneous and subcutaneous tissues involving two distinct chemokine groups. The first one dedicated to homeostatic dynamics of immune cells which maintains a healthy population of immune cells in the absence of injury. The second is the response specifically triggered by injury, infection, pain or malignancy 66.
It is important to note that much of the homeostatic immune cell dynamics of the skin in mammals specifically involves the vasculature of hair follicles 67–72. There is a strong association of immune cells with hair follicles starting from the morphogenesis stage itself 71,72. During human evolution, fur was lost. The density of hair follicles reduced substantially and this is expected to have affected the normal homeostatic immune cell dynamics in the skin. After losing fur, compensatory or alternative mechanisms independent of hair follicles should have evolved. But simultaneously after losing fur, the frequency of immune stimulation of skin by pricks, bruises, friction, insect bites, heat, UV exposure and other minor injuries would have increased considerably. This is in contrast to the other mammalian species to lose fur, namely the naked mole rat which spends most of the life in burrows with little exposure to many of the above stimuli.
We suggest here that when both types of pathways are almost always active, some redundancy is created due to which, the evolution of alternative baseline homeostatic pathways may have remained subnormal in humans. Injury stimulated pathways are likely to have played a major role in the immune cell dynamics of human skin owing to the high frequency of minor injuries after losing fur. Although not yet carefully examined at mechanistic level, this hypothesis is strengthened by the observed differences in humans versus other mammals in the signalling pathways of immune cell extravasation in the subcutaneous tissue. In humans, the altered association of immune mechanisms with hair follicles, suppression of CCL2-CCR2, CCXL8/IL-8 73, altered E-Selectin and P-Selectin signalling 74,75, absence of Siglec-5 76, altered STING and iNOS signalling 77, altered mast cell behaviour and evidence of selection on pro-inflammatory alleles 78 together strengthen our hypothesis although a much more careful contextual analysis and interpretation of these pathways is required. Since there exist several differences in the details of immune mechanisms across species 79–81 segregating the alterations specifically induced by the loss of fur in humans are difficult to mark out at this stage and careful primary work would be needed to examine this possibility.
Assuming that human skin immune dynamics has evolved differently than other mammals, it is possible to visualize the lifestyle related changes of modern humans. In today’s urban lifestyle, we live in an all-time cushioned environment and the frequency of minor injuries has come down dramatically. This is bound to alter the behaviour of immune cells considerably. If injury stimuli are reduced and the baseline homeostatic extravasation has evolved to work sub-normally, there would be a reduced flow of immune cells from blood to skin with modern lifestyle.
By our hypothesis, frequent minor injuries are necessary to maintain the normal immune cell population in human skin. The frequent small acute inflammatory responses would be normally accompanied and followed by enhanced lymphatic drainage, removal of immune cells participating in phagocytosis, antioxidant mechanisms, tissue repair and angiogenesis. The healing process involves a set of growth factors and many growth factor expressions are stimulated by minor injuries. In an injury free lifestyle these processes would also be sub-normal. What is more interesting to note is that even anticipation of injuries stimulates some of these mechanisms 6,82. Many of the growth factors involved in wound healing are secreted by the salivary glands following behaviors such as aggression 83–86 that increase the probability of injury. Salivary glands is the appropriate site for expression 82 because animals lick wounds and thereby supply the required growth factors directly.
On this background what do we expect to happen with modern lifestyle that is not only deficient in minor injuries but also in events of anticipation of injuries? The rate of turnover of immune cells is expected to reduce. The extravasation of immune cells will be slower and so would be the lymphatic drainage. Rapid clearing of chemo-attractants by lymphatic drainage is important for a sharper gradient guiding the cell migration. If more of the chemokines diffuse randomly and not quickly removed by lymphatic drainage, the gradient will be weaker reducing the cell migration further. Since phagocytic activity followed by clearance of effete cells also goes down, we expect greater accumulation of senescent cells in the subcutaneous tissue. When senescent cells accumulate, but fresh macrophages are not being recruited at a normal rate, it becomes an autocatalytic vicious cycle. Too many senescent cells accumulating and their signals unable to generate a sharp gradient because of subnormal lymphatic clearance can lead to accumulation of the signals which reduces further recruitment rather than enhancing it, leading to the phenomenon of senescence-associated secretory phenotype (SASP) 87–90. The signals given by senescent cells including interleukins, chemokines, cytokines, proteases, growth factors that are supposed to facilitate clearance of senescent cells are counterproductive because of the inability to form clear gradients. This has been demonstrated in studies showing that a large fraction of multiple cell types in the life style related disorders such as diabetics are senescent 59.
This can simply be the direct result of abnormally infrequent injury stimuli or it could be because of additional mechanisms. There is likely to be another mechanism evolved to optimize the investment in innate immunity. Investment trade-off is a known principle in evolution. Some trade-off between peripheral versus systemic immunity is shown in experimental challenges in invertebrates 91. The peripheral versus central immunity tradeoff is visualized in humans too in an evolutionary perspective 92. As the modern lifestyle is deficient in peripheral injuries on the one hand, it is likely to be accompanied by more frequent contagious diseases due to crowding. Therefore, disinvesting from peripheral immunity to support systemic immunity is a plausible response of the immune system to modern lifestyle. A simple way to achieve this is to further weaken the chemoattractant gradient generated from any cutaneous injury. That can be done by increasing the basal levels of some of the chemo-attractants 47. Since the gradient is because of the difference between local and basal levels of chemo-attractants, increasing basal levels would decrease rather than increase cell migration. This is achieved by expression of the chemokines by central organs such as visceral fat or kidney. The raised levels of circulating pCRP may also reduce granulocyte migration 93–96. Arguably this small investment in basal levels of chemo-attractants can save a greater cost of immune cell migration to sites where they are least likely to be needed 47.
The link with obesity and the so-called systemic inflammation is also likely to have evolved for optimizing immune response. Foraging behavior is optimized by finding the best trade-off between nutritional gains and foraging risk. At molecular level, this optimization is brought about by the interplay between leptin (a signal of stored energy) and cocaine- and amphetamine-regulated transcript (CART), (a signal of foraging risk) 97 .When there is enough of stored fat, the foraging drive becomes weaker, particularly if foraging is risky. Foraging increases the chances of injury. When foraging becomes unnecessary owing to stored fat, it makes sense to reduce the investment from peripheral innate immunity. When stored energy is minimal, foraging is necessary in spite of risk and this is where investing more in peripheral immunity is necessary. It would be most appropriate that the signals for this transition are given by adipose tissue itself. This transition needs to be sufficiently quick and plastic to be adaptive. However, if fat store remains high for a long time, as with the modern-day obesity, the plasticity may deteriorate 46,98,99.
Our synthesis necessitates a rethinking of the word systemic inflammation. If the main hallmarks of inflammation namely cell migration under chemoattractant gradient, phagocytosis, facilitated lymphatic turn over, and triggering the follow up healing cascades are all impaired or downregulated, calling it inflammation is absurd. What we call chronic systemic inflammation today is not a type of inflammation but actually a deficiency of the normal frequency of acute inflammations. The condition can easily be reversed by reversing the sedentary and injury free lifestyle. In deficiency diseases, supplementing what was deficient is the best remedy and no other drug can give comparable relief. Here physically active life with more or less normal injury and injury anticipation stimuli is the best remedy. Since the condition is not driven by an inflammation at all, anti-inflammatory treatments will at its best show marginal superficial difference and would not be able to reverse any of the conditions.
Currently since the popular perception is that chronic inflammation is damaging, the pathology of diabetes, cardiovascular disease, kidney disease and many types of neuronal disorders are said to be caused by chronic inflammation. If we reject the notion that chronic systemic inflammation is inflammation at all, alternative causes for the pathology would have to be sought. This, in fact, is likely to bring more clarity to the pathophysiology of these disorders and lead to more insightful approaches to treatments. We have already said that growth factor expressions are behavior responsive and the deficiency of the hunter gatherer behaviors for which our body is optimized characterizes modern lifestyle. Growth factors are expressed by every injury and are important and essential mediators in the healing process as well 100. The deficiency of the behaviors as well as of frequent minor injuries is bound to alter the growth factor dynamics. Since growth factors are involved in stem cell maintenance, angiogenesis, neuro-protection and metabolism among other functions, a cascade of changes can follow altered growth factor expression. Growth factors are critical for angiogenesis, revascularization and endothelial function. Endothelial dysfunction is the underlying cause of multiple disorders 101,102. The deficiency of a set of behaviors to which our physiology has been optimized is likely to be directly responsible for the pathological changes independent of inflammation 6.
Based on this concept a set of alternative pathophysiological hypotheses for different lifestyle related disorders which need to be tested with a differential prediction approach 103. It is very likely that giving up the chronic inflammation narrative will facilitate research on alternative possibilities of the true pathophysiological mechanisms of life style related disorders.
Testable predictions of the hypothesis:
If the hypothesis of deficiency of minor injuries and injury anticipating behaviors is true, we expect a number of outcomes. Some of these testable predictions are already known to be true. It is possible to subject them further to more specific tests.
(i)
Since the evolution of human skin immune system has taken a unique path, not shared by any of the laboratory animal models we expect that no animal models mimic the so called chronic systemic inflammatory condition in humans very closely and any research using partially resembling models would find only limited translational use, which appears to be true 104–108.
(ii)
By this hypothesis diabetics and others affected by lifestyle related disorders should be much more susceptible to cutaneous infections and non-healing wounds as compared to respiratory and other systemic infections 58–61.
(iii)
Impaired would healing is the most obvious prediction of our hypothesis. In contrast it is not a straightforward logical prediction of the systemic inflammation hypothesis. If the altered rate of migration of immune cells is a major cause of wound healing problems, enhancing the migration would facilitate wound healing which has been demonstrated. Exogenous granulocyte-macrophage colony-stimulating factor (GM-CSF) increased the influx of macrophages and neutrophils, followed by an increase in interleukin-6 and monocyte chemoattractant protein-1 production resulting into increase in neovascularization and stimulated wound healing 109,110. In addition, injuries and injury anticipating behaviors directly trigger a series of growth factors. Growth factors play a role in M1 to M2 transition as well as other processes in wound healing including neovascularization, epithelial cell growth and wound closure 111–113. We expect therefore that when the behavioral stimuli are normal, wound healing will be normal. This is testable with an epidemiological approach or a well-designed behavioral clinical trial.
(iv)
The foraging related component of our hypothesis expects that adipose tissue is the main organ to initiate the immunity transition. Therefore, obesity and related disorders would be correlated negatively with the mechanisms of peripheral immunity and cutaneous wound healing.
(v)
Evidence suggests that the lymphatic drainage system is crucial for the clearance of acute inflammatory response, removal of cytokines, catabolic factors and inflammatory cells from the site of injury/stimulus and other mediators of inflammation in rheumatoid arthritis 114, post myocardial infarction 115, and even the clearance of lipoproteins from inflamed atherosclerotic tissue 116. As expected by our hypothesis, lifestyle related disorders are strongly associated with lymphatic dysfunction, which leads to decreased lymphatic vessel density, decreased collecting lymphatic vessel pumping frequency, decreased lymphatic trafficking of immune cells, increased lymphatic vessel leakiness and changes in the gene expression patterns of lymphatic endothelial cells 117,118
(vi)
If reduced minor injury stimuli are responsible for the altered inflammatory state, increasing such stimuli would reverse the conditions. This is shown to happen by acupuncture and acupressure treatments 119–121. It is well-known that acupuncture and acupressure have substantial anti-inflammatory effects 122. Some of the studies show that even “sham” acupuncture i.e. stimulating the skin randomly independent of specific acupoints is anti-inflammatory which is compatible with our hypothesis 123–125. If any other behaviour/habit exposes the skin to more frequent injuries, it should reduce the incidence of the disorders believed to be caused by chronic systemic inflammation. Playing with pets, particularly young and subadults increases minor skin injuries caused by the playful bites and clawing by the animals. This is expected to reduce the incidence of so-called chronic inflammatory disorders and there is data supporting this expectation 126–129.
(vii)
Exercise partially reverses the sedentary lifestyle but it is also likely to induce the injury anticipation response. Behaviorally enriched exercises or active sports which mimics many hunter-gatherer behaviors such as chasing and catching something, aiming at something, attacking or defending something are expected to supplement the injury anticipation responses and thereby expected to reverse the innate immunity changes. Although there are no specific tests of behaviorally enriched exercises, exercises in general are known to resolve the condition. In obesity-related settings, aerobic exercise was found to decrease peri-lymphatic inflammatory cell accumulation, improve lymphatic function and reverse pathological changes in gene expression in lymphatic endothelial cells, which was independent of weight loss 117. In case of diabetic wound healing, exercise significantly increased angiogenesis, inhibited M1 macrophage infiltration and increased M2 macrophage count which significantly accelerated the wound healing process 130.
(viii)
The classically perceived role of exercise is that it burns calories and improves the energy balance, thereby reducing fat. The adipose tissue is said to mediate the systemic inflammation 131,132. An important prediction differentiating this perspective from our perspective is that by our hypothesis exercise benefits should be seen independent of weight loss. Wherever differentially tested, the advantages of exercise were found to be faster and independent of weight or fat loss 117,130. Although the adipose tissue is likely to be one of the mediators of the immune transition, there would be mechanisms that work independent of adiposity.
Since, in the lifestyle associated set of disorders, apart from fractional and inconsistent prevention of complications in some (but not all) of the clinical trials, the success of treatment is extremely limited 133–140, we need to cross-question the prevalent theories. It is likely that the limited effectiveness of treatments is because of a lack of clear perception of the true pathophysiology. Cross questioning the concept of chronic systemic inflammation is a small part of the bigger picture. Along with that we should also be open to alternative interpretation that can be tested using a model prediction matrix 141 and testing the predictions eventually.

VIII: Conclusions

At present there is too much conflation of mutually contradicting ideas in the concept of inflammation. Inflammation needs to be redefined as it has undergone profound transitions from cell-based to marker-based interpretations. The burden of history and simplicity has led to strong biases in the perception where multi-functionality of molecules is underappreciated. The example that macrophages and NK cells are critical in embryonic development and placentation, while B cells contribute to myelination and remyelination in the brain, states that these cells are not limited to just an “immune” function. Immune cells and molecules are integral to a wider function of networks and are not merely defence tools. These normal physiological functions of the so-called immune cells and the so-called inflammatory markers should be excluded from the definition of inflammation. Evolutionary perspective suggests that the reliance on molecular markers alone to define inflammation is problematic. It is important to understand that immune cell migration works on the basis of gradients of signal molecules, and their elevated systemic levels may weaken chemotactic gradients, impairing immune cell migration rather than enhancing it. Furthermore, the processes considered harmful today are likely to have been adaptive in ancestral contexts, hence the underlying ecological and lifestyle factors shape the immune dynamics. Complete rethinking of the concept of “low grade chronic systemic inflammation” is required, as it is paradoxical to label a condition as inflammation when classical hallmarks of inflammation are impaired or down-regulated.
Loss of fur was a human specific evolutionary change which brought about a number of changes in cutaneous immune challenges and the system evolved accordingly. This consideration gives us a new outlook and leads to a novel alternative interpretation of the so called chronic systemic inflammation, which is not inflammation at all.
Therefore, the word inflammation should only be used in relevant contexts and need not always be associated in the context of elevated levels of one or more markers. The testable predictions and realities match according to the evolutionary perspective. Hence, inflammation must be carefully redefined recognizing its underlying framework that integrates molecular, cellular, and even evolutionary insights.

References

  1. Rocha, M. & Silva, E. A Brief Survey of the History of Inflammation. Agents and Actions vol. 8 (1978).
  2. Russell P. Tracy. The Five Cardinal Signs of Inflammation Calor, Dolor, Rubor, Tumor and Penuria Apologies to Aulus Cornelius Celsus, De medicina, c. A.D. 25. [CrossRef]
  3. Cavaillon, J. M. Once upon a time, inflammation. Journal of Venomous Animals and Toxins Including Tropical Diseases vol. 27 (2021). Preprint at. [CrossRef]
  4. Jiménez-Gracia, L. et al. Interpretable inflammation landscape of circulating immune cells. Nat. Med. (2026). [CrossRef]
  5. Street, M. E., Moghetti, P. & Chiarelli, F. The Multiple Functions of Insulin Put into Perspective: From Growth to Metabolism, and from Well-Being to Disease. International Journal of Molecular Sciences 2023, Vol. 24, Page 200 24, 200 (2022). [CrossRef]
  6. Watve, M. Doves, diplomats, and diabetes: A darwinian interpretation of type 2 diabetes and related disorders. Doves, Diplomats, and Diabetes: A Darwinian Interpretation of Type 2 Diabetes and Related Disorders 1–380 (2013). [CrossRef]
  7. Kern, W. et al. Improving Influence of Insulin on Cognitive Functions in Humans. Neuroendocrinology 74, 270–280 (2001). [CrossRef]
  8. Neirijnck, Y., Papaioannou, M. D. & Nef, S. The Insulin/IGF System in Mammalian Sexual Development and Reproduction. Int. J. Mol. Sci. 20, (2019). [CrossRef]
  9. Diwekar-Joshi, M. & Watve, M. Does insulin signalling decide glucose levels in the fasting steady state? (2019). Preprint at. [CrossRef]
  10. Kulkarni, S., Sharda, S. & Watve, M. Bi-stability in type 2 diabetes mellitus multi-organ signalling network. PLoS One 12, (2017). [CrossRef]
  11. Han, Y., You, X., Xing, W., Zhang, Z. & Zou, W. Paracrine and endocrine actions of bone - The functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Research vol. 6 (2018). Preprint at. [CrossRef]
  12. Moser, S. C. & van der Eerden, B. C. J. Osteocalcin — A versatile bone-derived hormone. Frontiers in Endocrinology vol. 10 (2019). Preprint at. [CrossRef]
  13. Srivastava, R. K., Sapra, L. & Mishra, P. K. Osteometabolism: Metabolic Alterations in Bone Pathologies. Cells vol. 11 (2022). Preprint at. [CrossRef]
  14. Barthelemy, J., Bogard, G. & Wolowczuk, I. Beyond energy balance regulation: The underestimated role of adipose tissues in host defense against pathogens. Front. Immunol. 14, (2023). [CrossRef]
  15. Chang, M. L., Yang, Z. & Yang, S. S. Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression. Int. J. Mol. Sci. 21, 1–36 (2020). [CrossRef]
  16. Roger, T., Froidevaux, C., Martin, C. & Calandra, T. Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of toll-like receptor 4 (TLR4). in Journal of Endotoxin Research vol. 9 119–123 (2003).
  17. Mitchell, R. A., Metz, C. N., Peng, T. & Bucala, R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF): Regulatory role in cell proliferation and glucocorticoid action. Journal of Biological Chemistry 274, 18100–18106 (1999).
  18. Lang, T. et al. Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nat. Commun. 9, (2018). [CrossRef]
  19. Takahashi, K. et al. Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir. Res. 10, (2009). [CrossRef]
  20. Ranganathan, V. et al. Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis. Arthritis and Rheumatology 69, 1796–1806 (2017). [CrossRef]
  21. Roger, T. et al. Macrophage migration inhibitory factor deficiency is associated with impaired killing of gram-negative bacteria by macrophages and increased susceptibility to Klebsiella pneumoniae sepsis. Journal of Infectious Diseases 207, 331–339 (2013). [CrossRef]
  22. Wang, Z. et al. Inhibition of Macrophage Migration Inhibitory Factor Reduces Diabetic Nephropathy in Type II Diabetes Mice. Inflammation 37, 2020–2029 (2014). [CrossRef]
  23. Matejuk, A. et al. MIF contribution to progressive brain diseases. Journal of Neuroinflammation vol. 21 (2024). Preprint at. [CrossRef]
  24. Kleemann, R. & Bucala, R. Macrophage migration inhibitory factor: Critical role in obesity, insulin resistance, and associated comorbidities. Mediators of Inflammation vol. 2010 Preprint at (2010). [CrossRef]
  25. Abreu, M. M., Chocron, A. F. & Smadja, D. M. From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy. Frontiers in Immunology vol. 16 (2025). Preprint at. [CrossRef]
  26. Palanivelu, L., Liu, C. H. & Lin, L. T. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Frontiers in Immunology vol. 13 (2023). Preprint at. [CrossRef]
  27. Navarro Quiroz, R. et al. Multiscale information processing in the immune system. Frontiers in Immunology vol. 16 (2025). Preprint at. [CrossRef]
  28. Goosby, B. J. & Cheadle, J. E. The Immune System Is a Complex System: Inflammatory Morbidity and Systemic Racism. Kolner Z. Soz. Sozpsychol. 76, 713–744 (2024). [CrossRef]
  29. Sharma, R. et al. Temporal Control of Decidual Inflammation by HOXA10 is Essential for Implantation and its Dysregulation is Associated with Early Pregnancy Loss. [CrossRef]
  30. Chambers, M. et al. Macrophage Plasticity in Reproduction and Environmental Influences on Their Function. Frontiers in Immunology vol. 11 (2021). Preprint at. [CrossRef]
  31. Jang, J. H., Sung, J. H. & Huh, J. Y. Diverse Functions of Macrophages in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Inflammation and Metabolism. Immune Network vol. 25 (2025). Preprint at. [CrossRef]
  32. Park, M., Kim, Y. S. & Song, H. Macrophages: a double-edged sword in female reproduction and disorders. Experimental and Molecular Medicine vol. 57 285–297 (2025). Preprint at. [CrossRef]
  33. Chen, S., Zhu, H. & Jounaidi, Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduction and Targeted Therapy vol. 9 (2024). Preprint at. [CrossRef]
  34. Fu, B. et al. Natural Killer Cells Promote Fetal Development through the Secretion of Growth-Promoting Factors. Immunity 47, 1100-1113.e6 (2017). [CrossRef]
  35. Hanna, J. et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12, 1065–1074 (2006). [CrossRef]
  36. Yagel, S. The developmental role of natural killer cells at the fetal-maternal interface. American Journal of Obstetrics and Gynecology vol. 201 344–350 (2009). Preprint at. [CrossRef]
  37. Martirosyan, A., Kriegova, E. & Manukyan, G. NK cell dysfunction in antiphospholipid syndrome. Frontiers in Immunology vol. 16 (2025). Preprint at. [CrossRef]
  38. Veremeyko, T., Barteneva, N. S., Vorobyev, I. & Ponomarev, E. D. The Emerging Role of Immunoglobulins and Complement in the Stimulation of Neuronal Activity and Repair: Not as Simple as We Thought. Biomolecules vol. 14 (2024). Preprint at. [CrossRef]
  39. Halperin, S. T., ’T Hart, B. A., Luchicchi, A. & Schenk, G. J. The Forgotten Brother: The Innate-like B1 Cell in Multiple Sclerosis. Biomedicines 10, (2022).
  40. Ihunwo, A. O., Perego, J., Martino, G., Vicenzi, E. & Panina-Bordignon, P. Neurogenesis and Viral Infection. Frontiers in Immunology vol. 13 (2022). Preprint at. [CrossRef]
  41. Tanabe, S. & Yamashita, T. Function of Lymphocytes in Oligodendrocyte Development. Neuroscientist vol. 26 74–86 (2020). Preprint at. [CrossRef]
  42. Rodriguez-mogeda, C. et al. Breaching Brain Barriers: B Cell Migration in Multiple Sclerosis. Biomolecules vol. 12 (2022). Preprint at. [CrossRef]
  43. Tanabe, S. & Yamashita, T. B-1a lymphocytes promote oligodendrogenesis during brain development. Nat. Neurosci. 21, 506–516 (2018). [CrossRef]
  44. Morimoto, K. & Nakajima, K. Role of the Immune System in the Development of the Central Nervous System. Front. Neurosci. 13, 468190 (2019). [CrossRef]
  45. Giudice, M. Del & Gangestad, S. W. Rethinking IL-6 and CRP Rethinking IL-6 and CRP: Why They Are More Than Inflammatory Biomarkers, and Why It Matters. Brain, Behavior, and Immunity vol. 70 (2018).
  46. Kistner, T. M., Pedersen, B. K. & Lieberman, D. E. Interleukin 6 as an energy allocator in muscle tissue. Nature Metabolism vol. 4 170–179 (2022). Preprint at. [CrossRef]
  47. Watve, M. & Mandani, S. Why Serum Chemokine Levels Are Raised in Insulin Resistance Syndrome: An Immune Reversal Hypothesis. CURRENT SCIENCE vol. 95 (2008). [CrossRef]
  48. Kimura, Y. (2011). Neutrophil chemotaxis in multiple chemoattractant gradients. http://hdl.handle.net/2142/18520 (Dissertation/Repository).
  49. Diao, G. et al. Prostaglandin E2 serves a dual role in regulating the migration of dendritic cells. Int. J. Mol. Med. 47, 207–218 (2021). [CrossRef]
  50. Mai, J., Fok, L., Gao, H., Zhang, X. & Poo, M. M. Axon initiation and growth cone turning on bound protein gradients. Journal of Neuroscience 29, 7450–7458 (2009). [CrossRef]
  51. Osma-Garcia, I. C., Punzón, C., Fresno, M. & Díaz-Muñoz, M. D. Dose-dependent effects of prostaglandin E2 in macrophage adhesion and migration. Eur. J. Immunol. 46, 677–688 (2016). [CrossRef]
  52. Savill, P. Spironolactone in heart failure with preserved ejection fraction. Practitioner 258, 10 (2014).
  53. Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M. & Welty, F. K. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. J. Am. Coll. Cardiol. 87, 1381–1404 (2026). [CrossRef]
  54. Jolly, S. S. et al. Colchicine in Acute Myocardial Infarction. New England Journal of Medicine 392, 633–642 (2025).
  55. Ridker, P. M. et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine 380, 752–762 (2019). [CrossRef]
  56. Tardif, J.-C. et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine 381, 2497–2505 (2019). [CrossRef]
  57. Mandrola, J.M. Rethinking Inflammation and ASCVD: Four lessons from the ZEUS trial. Medscape News and Perspectives Aug 12, (2026).
  58. Wilkinson, H. N. et al. Elevated Local Senescence in Diabetic Wound Healing Is Linked to Pathological Repair via CXCR2. Journal of Investigative Dermatology 139, 1171-1181.e6 (2019). [CrossRef]
  59. Marjana Tomic-Canic & Luisa A. DiPietro. Cellular Senescence in Diabetic Wounds: When Too Many Retirees Stress the System. Journal of Investigative Dermatology 139, 999–1001 (2019). [CrossRef]
  60. Prado, T. P., Morari, J. & Araújo, E. P. Molecular and morphological alterations in uninjured skin of streptozotocin-induced diabetic mice. Brazilian Journal of Medical and Biological Research 56, (2023). [CrossRef]
  61. Ren, B., Wang, Z., Rawaf, S. & Tabche, C. Association between obesity and the risk of skin and soft tissue infections in European populations: A systematic review. IJID Regions vol. 19 Preprint at (2026). [CrossRef]
  62. McDade, T. W. Three common assumptions about inflammation, aging, and health that are probably wrong. Proc. Natl. Acad. Sci. U. S. A. 120, (2023). [CrossRef]
  63. Mezu-Ndubuisi, O. J. & Maheshwari, A. Role of macrophages in fetal development and perinatal disorders. Pediatric Research vol. 90 513–523 (2021). Preprint at. [CrossRef]
  64. Watve, M. & Diwekar-Joshi, M. What to expect from an evolutionary hypothesis for a human disease: The case of type 2 diabetes. HOMO- Journal of Comparative Human Biology 67, 349–368 (2016). [CrossRef]
  65. Bolnick, D. I. et al. Evolutionary Immunology. Annu. Rev. Ecol. Evol. Syst. 56, 27–51 (2025). [CrossRef]
  66. Lafouresse, F. & Groom, J. R. A task force against local inflammation and cancer: Lymphocyte trafficking to and within the skin. Front. Immunol. 9, 419022 (2018). [CrossRef]
  67. Lee, S. A., Li, K. N. & Tumbar, T. Stem cell-intrinsic mechanisms regulating adult hair follicle homeostasis. Exp. Dermatol. 30, 430–447 (2021). [CrossRef]
  68. Grose, R. et al. Skin and hair follicle integrity is crucially dependent on Beta-1 integrin expression on keratinocytes. (2000). [CrossRef]
  69. Nagao, K. et al. Stress-induced production of chemokines by hair follicles regulates the trafficking of dendritic cells in skin. Nature Immunology 2012 13:8 13, 744–752 (2012). [CrossRef]
  70. Song, W. et al. The Skin Microenvironment: A Dynamic Regulator of Hair Follicle Development, Cycling and Disease. Biomolecules 2025, Vol. 15, Page 1335 15, 1335 (2025). [CrossRef]
  71. Christoph, T. et al. The human hair follicle immune system: cellular composition and immune privilege. British Journal of Dermatology 142, 862–873 (2000). [CrossRef]
  72. Paus, R., Christoph, T. & Müller-Röver, S. Immunology of the Hair Follicle: A Short Journey into terra incognita. Journal of Investigative Dermatology Symposium Proceedings 4, 226–234 (1999). [CrossRef]
  73. Wang, J. N. & Li, M. The Immune Function of Keratinocytes in Anti-Pathogen Infection in the Skin. Int. J. Dermatol. Venereol. 3, 231–238 (2020). [CrossRef]
  74. Longbiao, Y. et al. Divergent Inducible Expression of P-Selectin and E-Selectin in Mice and Primates. Blood 94, 3820–3828 (1999).
  75. Liu, Z. et al. Differential regulation of human and murine P-selectin expression and function in vivo. Journal of Experimental Medicine 207, 2975–2987 (2010). [CrossRef]
  76. Nguyen, D. H., Hurtado-Ziola, N., Gagneux, P. & Varki, A. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. U. S. A. 103, 7765–7770 (2006). [CrossRef]
  77. Weinberg, J. et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 86, 1184–1195 (1995).
  78. Le Souëf, P. N., Goldblatt, J. & Lynch, N. R. Evolutionary adaptation of inflammatory immune responses in human beings. Lancet 356, 242–244 (2000). [CrossRef]
  79. Gregory, D. J. et al. Molecular profiles of blood from numerous species that differ in sensitivity to acute inflammation. Molecular Medicine 2024 30:1 30, 280- (2024). [CrossRef]
  80. Barreiro, L. B., Marioni, J. C., Blekhman, R., Stephens, M. & Gilad, Y. Functional comparison of innate immune signaling pathways in primates. PLoS Genet. 6, 1–13 (2010). [CrossRef]
  81. Bjornson-Hooper, Z. B. et al. A comprehensive atlas of immunological differences between humans, mice and non-human primates. bioRxiv 574160 (2019). [CrossRef]
  82. Aloe, L. et al. Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 91, 10440 (1994). [CrossRef]
  83. Byyny, R. L., Orth, D. N., Cohen, S. & Doyne, E. S. Epidermal Growth Factor: Effects of Androgens and Adrenergic Agents. Endocrinology 95, 776–782 (1974). [CrossRef]
  84. Noguchi, S., Ohba, Y. & Oka, T. Involvement of Epidermal Growth Factor Deficiency in Pathogenesis of Oligozoospermia in Streptozotocin-Induced Diabetic Mice. Endocrinology 127, 2136–2140 (1990). [CrossRef]
  85. Lakshmanan, J. Aggressive behavior in adult male mice elevates serum nerve growth factor levels. 250, (1986). [CrossRef]
  86. NEXØ, E., HOLLENBERG, M. D. & BING, J. Aggressive behaviour in mice provokes a marked increase in both plasma epidermal growth factor and renin. Acta Physiol. Scand. 111, 367–371 (1981). [CrossRef]
  87. Wang, B., Han, J., Elisseeff, J. H. & Demaria, M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nature Reviews Molecular Cell Biology vol. 25 958–978 (2024). Preprint at. [CrossRef]
  88. Lopes-Paciencia, S. et al. The senescence-associated secretory phenotype and its regulation. Cytokine 117, 15–22 (2019). [CrossRef]
  89. Alqahtani, S. et al. SASP Modulation for Cellular Rejuvenation and Tissue Homeostasis: Therapeutic Strategies and Molecular Insights. Cells vol. 14 (2025). Preprint at. [CrossRef]
  90. Saito, Y., Yamamoto, S. & Chikenji, T. S. Role of cellular senescence in inflammation and regeneration. Inflammation and Regeneration vol. 44 (2024). Preprint at. [CrossRef]
  91. Seal, S. et al. TRACKING EVOLUTIONARY COSTS OF IMMUNE ADAPTATION AGAINST SINGLE VERSUS COINFECTING PATHOGENS. (2026). [CrossRef]
  92. West-Eberhard, M. J. Nutrition, the visceral immune system, and the evolutionary origins of pathogenic obesity. (2019). [CrossRef]
  93. Bennett, J. M., Reeves, G., Billman, G. E. & Sturmberg, J. P. Inflammation-nature’s way to efficiently respond to all types of challenges: Implications for understanding and managing ‘the epidemic’ of chronic diseases. Front. Med. (Lausanne). 5, (2018). [CrossRef]
  94. Nagasawa, M. CRP (C-Reactive Protein) Revisited: An Old Yet New Biomarker of Acute and Chronic Inflammation. Cells vol. 15 (2026). Preprint at. [CrossRef]
  95. Olson, M. E. et al. A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: differentiating pentameric and modified CRP isoform effects. Frontiers in Immunology vol. 14 (2023). Preprint at. [CrossRef]
  96. Heuertz, R. M., Tricomi, S. M., Ezekiel, U. R. & Webster, R. O. C-reactive protein inhibits chemotactic peptide-induced p38 mitogen- activated protein kinase activity and human neutrophil movement. Journal of Biological Chemistry 274, 17968–17974 (1999). [CrossRef]
  97. Baig, U., Lokhande, L., Lalwani, P., Chawla, S. & Watve, M. Foraging theory and the propensity to be obese: an alternative to thrift. HOMO 70, 193–216 (2019). [CrossRef]
  98. Bilal, M. et al. Deletion of Tgf-β1 From CD206+ M2 Macrophages Ameliorates Obesity-Induced Suppression of Myogenesis and AMPK Phosphorylation in Skeletal Muscle. J. Cachexia Sarcopenia Muscle 17, (2026). [CrossRef]
  99. Hou, C., Bolt, K. & Bergman, A. A General Life History Theory for Effects of Caloric Restriction on Health Maintenance. BMC Syst. Biol. 5, (2011). [CrossRef]
  100. Chandra, P., Faizan, M., Porwal, M., Sharma, H. & Sachan, N. An Overview and Review of Growth Factors in Wound Healing: Emerging Trends and Innovations. Curr. Diabetes Rev. 22, (2026). [CrossRef]
  101. Ackermann, M. R. Inflammation and Healing. in Pathologic Basis of Veterinary Disease Expert Consult 73-131.e2 (Elsevier Inc., 2017). [CrossRef]
  102. Dzau, V. J. & Gibbons, G. H. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 18, III-115-III–121 (1991). [CrossRef]
  103. Watve, M. & Sardeshmukh, A. K. “Vitaction” deficiency: a possible root cause for multiple lifestyle disorders including Alzheimer’s disease. Exploration of Neuroprotective Therapy 4, 108–118 (2024). [CrossRef]
  104. Seemann, S., Zohles, F. & Lupp, A. Comprehensive comparison of three different animal models for systemic inflammation. J. Biomed. Sci. 24, 60 (2017). [CrossRef]
  105. Rafiyan, M., Sadeghmousavi, S., Akbarzadeh, M. & Rezaei, N. Experimental animal models of chronic inflammation. Current Research in Immunology 4, 100063 (2023). [CrossRef]
  106. Golforoush, P., Yellon, D. M. & Davidson, S. M. Mouse models of atherosclerosis and their suitability for the study of myocardial infarction. Basic Res. Cardiol. 115, 73 (2020). [CrossRef]
  107. Ilyas, I. et al. Mouse models of atherosclerosis in translational research. Trends Pharmacol. Sci. 43, 920–939 (2022). [CrossRef]
  108. Camacho, P., Fan, H., Liu, Z. & He, J.-Q. Small Mammalian Animal Models of Heart Disease. Am J Cardiovasc Dis vol. 6 www.AJCD.us/ (2016).
  109. Fang, Y. et al. Granulocyte-macrophage colony-stimulating factor enhances wound healing in diabetes via upregulation of proinflammatory cytokines. British Journal of Dermatology 162, 478–486 (2010). [CrossRef]
  110. Yönem, A., Çakir, B., Güler, S., Azal, Ö. & Çorakçi, A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes. Metab. 3, 332–337 (2001). [CrossRef]
  111. Nishikoba, N. et al. HGF-MET Signaling Shifts M1 Macrophages Toward an M2-Like Phenotype Through PI3K-Mediated Induction of Arginase-1 Expression. Front. Immunol. 11, (2020). [CrossRef]
  112. Zhang, Y. H., He, M., Wang, Y. & Liao, A. H. Modulators of the balance between M1 and M2 macrophages during pregnancy. Front. Immunol. 8, (2017). [CrossRef]
  113. Yaseen, H. & Khamaisi, M. Skin well-being in diabetes: Role of macrophages. Cellular Immunology vol. 356 Preprint at (2020). [CrossRef]
  114. Bouta, E. M. et al. Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis. Nature Reviews Rheumatology vol. 14 94–106 (2018).Preprint at. [CrossRef]
  115. Vieira, J. M. et al. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction. Journal of Clinical Investigation 128, 3402–3412 (2018). [CrossRef]
  116. Yeo, K. P., Lim, H. Y. & Angeli, V. Leukocyte trafficking via lymphatic vessels in atherosclerosis. Cells vol. 10 (2021). Preprint at. [CrossRef]
  117. Hespe, G. E. et al. Exercise training improves obesity-related lymphatic dysfunction. Journal of Physiology 594, 4267–4282 (2016). [CrossRef]
  118. Galkowska, H., Wojewodzka, U. & Olszewski, W. L. Low recruitment of immune cells with increased expression of endothelial adhesion molecules in margins of the chronic diabetic foot ulcers. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 13(3), 248–254 (2005). [CrossRef]
  119. Oh, J. E. & Kim, S. N. Anti-Inflammatory Effects of Acupuncture at ST36 Point: A Literature Review in Animal Studies. Frontiers in Immunology vol. 12 (2022). Preprint at. [CrossRef]
  120. Li, N. et al. The Anti-Inflammatory Actions and Mechanisms of Acupuncture from Acupoint to Target Organs via Neuro-Immune Regulation. Journal of Inflammation Research vol. 14 7191–7224 (2021). Preprint at. [CrossRef]
  121. Lin, W. C. et al. The Anti-Inflammatory Actions of Auricular Point Acupressure for Chronic Low Back Pain. Evidence-based Complementary and Alternative Medicine 2015, (2015). [CrossRef]
  122. Li, N. et al. The Anti-Inflammatory Actions and Mechanisms of Acupuncture from Acupoint to Target Organs via Neuro-Immune Regulation. J. Inflamm. Res. 14, 7191–7224 (2021). [CrossRef]
  123. Kaptchuk, T. J. Placebo Effects in Acupuncture. Med. Acupunct. 32, 352–356 (2020). [CrossRef]
  124. Musial, F. Acupuncture for the treatment of pain – a mega-placebo? Front. Neurosci. 13, 443062 (2019). [CrossRef]
  125. Näslund, J., Lundeberg, T., Lund, I. & Sing, A. Is Placebo Acupuncture What It Is Intended to Be? Evid. Based. Complement. Alternat. Med. 2011, 932407 (2011). [CrossRef]
  126. Qureshi, A. I., Memon, M. Z., Vazquez, G. & Suri, M. F. K. Cat ownership and the Risk of Fatal Cardiovascular Diseases. Results from the Second National Health and Nutrition Examination Study Mortality Follow-up Study. J. Vasc. Interv. Neurol. 2, 132 (2009).
  127. Surma, S., Oparil, S. & Narkiewicz, K. Pet Ownership and the Risk of Arterial Hypertension and Cardiovascular Disease. Curr. Hypertens. Rep. 24, 295 (2022). [CrossRef]
  128. Ogechi, I. et al. Pet Ownership and the Risk of Dying from Cardiovascular Disease Among Adults Without Major Chronic Medical Conditions. High Blood Pressure & Cardiovascular Prevention 2016 23:3 23, 245–253 (2016). [CrossRef]
  129. Levine, G. N. et al. Pet ownership and cardiovascular risk: A scientific statement from the American Heart Association. Circulation 127, 2353–2363 (2013).
  130. Kawanishi, M. et al. Exercise-induced increase in M2 macrophages accelerates wound healing in young mice. Physiol. Rep. 10, (2022). [CrossRef]
  131. Chait, A. & den Hartigh, L. J. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med. 7, (2020). [CrossRef]
  132. Adolph, T. E., Grander, C., Grabherr, F. & Tilg, H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int. J. Mol. Sci. 18, (2017). [CrossRef]
  133. PubPeer - 5-year follow-up of the randomised Diabetes Remission Clinic... https://pubpeer.com/publications/BB3FA543038FF3DF3F83B449F8E5AA.
  134. Group, T. A. to C. C. R. in D. S. Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine 358, 2545–2559 (2008).
  135. Investigators, T. N.-S. S. Intensive versus Conventional Glucose Control in Critically Ill Patients. New England Journal of Medicine 360, 1283–1297 (2009).
  136. Boussageon, R., Pouchain, D. & Renard, V. Prevention of complications in type 2 diabetes: is drug glucose control evidence based? British Journal of General Practice 67, 85–87 (2017). [CrossRef]
  137. Lee, C. G. et al. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 44, 2775–2782 (2021). [CrossRef]
  138. Ojha, A., Vidwans, H. & Watve, M. Does Sugar Control Arrest Complications in Type 2 Diabetes? Examining the Rigour in Statistical Methods and Causal Inference in Clinical Trials. (2023). [CrossRef]
  139. Adigbli, D. et al. A Patient-Level Meta-Analysis of Intensive Glucose Control in Critically Ill Adults. NEJM Evidence 3, (2024). [CrossRef]
  140. Natale, P., Palmer, S. C., Tunnicliffe, D. J., Toyama, T. & Strippoli, G. F. M. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst. Rev. 2023, CD015849 (2023).
  141. Ojha, A. & Watve, M. Reduced Blood to Brain Glucose Transport as the Cause for Hyperglycemia: A Model That Resolves Multiple Anomalies in Type 2 Diabetes. Qeios 6, (2024).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.